TODAY'S MARKET INTELLIGENCE
Taienkang: Wholly-Owned Subsidiary's Cisplatin Polymer Micelle Injection Gets Clinical Trial Approval
English summary
The cisplatin polymer micelle injection developed by Taienkang's wholly-owned subsidiary Shandong Huabo Kaisheng Biotech received clinical trial approval from the NMPA for monotherapy in advanced malignant tumors.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence